Bifenazate, a potent acaricide that targets mitochondrial complex III, exhibits selective toxicity (>280-fold) toward phytophagous mites versus predatory mites. Here, a systematic study was conducted to clarify the selective mechanism. Nontarget factors were excluded through epidermal penetration tests and assessment of detoxification enzymes' activities. Quantification of IC 50 values, ATP content, and reactive oxygen species (ROS) levels revealed that differences in drug-target binding determine the toxicity selectivity. Structural modeling and molecular docking revealed that variations in key amino acid sites within the cytochrome b (cytb) target might regulate this selectivity, which was validated through a microscale thermophoresis assay. Significant disparities were observed in the binding affinity between bifenazate and recombinant cytb proteins derived from phytophagous mites and predatory mites. Mutating isoleucine 139 to leucine notably reduced the binding affinity of bifenazate to cytb. Insights into bifenazate selectivity between phytophagous and predatory mites inform a basis for developing compounds that target cytochrome b .